NCT06952894

Brief Summary

This sponsor-initiated prospective observational study aims to demonstrate the feasibility and efficacy of RUS Lung Surgical Navigation System in patients undergoing minimally invasive thoracic surgery(MITS). The trial will enroll 36 patients who undergo video-assisted or robot-assisted thoracoscopic surgery using RUS Lung. The study will be conducted across two medical centers."

  • Investigational Medical Device: RUS Lung (Endoscopic Imaging Treatment Planning Software)
  • Clinical Trial duration: 12 months from IRB approval
  • Target number of subjects: Total of 36 participants

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
34

participants targeted

Target at below P25 for not_applicable lung-cancer

Timeline
Completed

Started May 2025

Shorter than P25 for not_applicable lung-cancer

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 9, 2025

Completed
22 days until next milestone

First Posted

Study publicly available on registry

May 1, 2025

Completed
11 days until next milestone

Study Start

First participant enrolled

May 12, 2025

Completed
16 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 28, 2025

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

August 11, 2025

Completed
Last Updated

September 3, 2025

Status Verified

August 1, 2025

Enrollment Period

16 days

First QC Date

April 9, 2025

Last Update Submit

August 26, 2025

Conditions

Keywords

lung cancer3D model3 dimensionalsegmentectomyrobot-assisted thoracoscopic surgeryvideo-assisted thoracoscopic surgery

Outcome Measures

Primary Outcomes (1)

  • The concordance rate of tumor location across CT, RUS Lung, and surgery

    Overall feasibility of the RUS Lung system will be evaluated by 3 factors as below. 1. CT turn-around time: the duration between uploading of preoperative CT and downloading the 3D model file 2. The stability of the RUS Lung system 3. The concordance rate of tumor location across CT, RUS Lung, and surgery

    The operative day (operative day ± 5 days)

Secondary Outcomes (1)

  • The degree of consistency between surgical planning using the RUS lung system and actual surgical findings.

    From enrollment to the end of treatment at 2 weeks

Study Arms (1)

RUS Group

EXPERIMENTAL

Patients undergo video-assisted or robot-assisted thoracoscopic surgery using RUS Lung software.

Device: RUS Lung

Interventions

RUS LungDEVICE

The RUS Lung is an endoscopic imaging treatment planning software program. It creates a patient-specific simulation of the thoracic surgical environments, allowing for the visualization of tumor, bronchovascular structures and thoracic organs during the surgical planning process and the operation. RUS Lung utilizes preoperative CT images of the patients to segment tumor, organs, blood vessels, and bronchus and reconstructs them into a 3D model. Although there is no direct intervention on the patient, the surgeon uses RUS Lung as a surgical navigation tool to simulate the surgery before performing the actual procedure.

RUS Group

Eligibility Criteria

Age19 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Individuals who were diagnosed with lung caner (tumor size≤3cm)
  • Individuals aged 19 or older
  • Individuals who who are able to undergo CT imaging according to the established protocol
  • Individuals who have voluntarily given written consent to participate in this clinical trial

You may not qualify if:

  • Vulnerable subjects
  • Individuals who who are not able to undergo CT imaging according to the established protocol
  • Individuals who are expected to have severe adhesions
  • Individuals who are unable to follow the study procedures and are deemed inappropriate for participation

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Severance Hospital

Seoul, South Korea

Location

MeSH Terms

Conditions

Lung Neoplasms

Condition Hierarchy (Ancestors)

Respiratory Tract NeoplasmsThoracic NeoplasmsNeoplasms by SiteNeoplasmsLung DiseasesRespiratory Tract Diseases

Study Officials

  • Chang Young Lee, M.D.,Ph.D.

    Severance Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 9, 2025

First Posted

May 1, 2025

Study Start

May 12, 2025

Primary Completion

May 28, 2025

Study Completion

August 11, 2025

Last Updated

September 3, 2025

Record last verified: 2025-08

Locations